Zobrazeno 1 - 7
of 7
pro vyhledávání: '"WEIWU YE"'
Publikováno v:
Discrete Dynamics in Nature and Society, Vol 2022 (2022)
Martial arts education has a relatively comprehensive educational function. Compared with other educational methods, it has some unique features. When martial arts education carries out moral education, it not only attaches importance to the teaching
Externí odkaz:
https://doaj.org/article/0549a156c4224fe987485b041ef6db41
Autor:
Zhanhong Chen, Yabing Zheng, Wenming Cao, Yuzi Zhang, Zhengyi Zhao, Guoqiang Wang, Jing Zhao, Shangli Cai, Xiying Shao, Jian Huang, Weiwu Ye, Yuan Huang, Wei Li, Xiang Huang, Hao Wu, Xiaojia Wang, Yongmei Yin
Publikováno v:
Cancer Medicine, Vol 8, Iss 12, Pp 5544-5553 (2019)
Abstract Background Previous case reports have shown the promising antitumor activity of everolimus in solid tumors containing molecular aberrations in PI3K/ATK/mTOR pathway, however, whether it is effective in patients with breast cancer remains unk
Externí odkaz:
https://doaj.org/article/99472f1ad594491da252484cc3a0986a
Autor:
Wen-Ming Cao, Xiaojia Wang, Jian Liu, Lili Wang, Xiaodong Zhang, Jiani Pan, Weiwu Ye, Zhanhong Chen, Yabing Zheng, Xiying Shao, Yuanji Xu
Publikováno v:
Journal of Clinical Oncology. 40:e13576-e13576
e13576 Background: BRCA1/BRCA2, representing as an important genetic biomarker of breast cancer (BCA), can provide clinically significant implications for personalized risk assessment, effective treatment option, and prognostic prediction. Methods: W
Autor:
Zhanhong Chen, Xiaojia Wang, Jian Huang, Yabing Zheng, Xiying Shao, Wenming Cao, Junqing Chen, Weiwu Ye, Huang Ping, Guangliang Li, Lei Lei, Lei Shi, Yuan Huang, Weibin Zou, Rong Wang, Xia-Bo Shen, Caijin Lou
Publikováno v:
Journal of Clinical Oncology. 40:1072-1072
1072 Background: Apatinib is an oral, highly potent tyrosine-kinase inhibitor targeting VEGFR2. A series of clinical studies have shown that anti-angiogenic drugs combined with chemotherapy enable to improve the efficacy of HER2-negative advanced/met
Publikováno v:
Journal of Clinical Oncology. 40:e22525-e22525
e22525 Background: BARD1 (BRCA1-associated ring domain 1), nuclear partner of BRCA1, has been recognized as a breast cancer predisposition gene. Recently, two large-scale population-based case–control studies confirmed that germline loss-of-functio
Publikováno v:
Journal of Clinical Oncology. 40:e13575-e13575
e13575 Background: Homologous recombination deficiency (HRD) can be resulted from dysfunction of BRCA and is associated with sensitivity to platinum, PARP inhibitor and other DNA-damaging drugs. The results from a neoadjuvant trial showed that pathol
Autor:
XIYING SHAO, LEI LUO, YONG GUO, XIAOHONG XU, DEHOU DENG, JIANGUO FENG, YUHENG DING, HANZHOU MOU, PING HUANG, LEI SHI, YUAN HUANG, WEIWU YE, CAIJIN LOU, ZHANHONG CHEN, YABING ZHENG, XIAOJIA WANG
Publikováno v:
Oncology Letters; Nov2017, Vol. 14 Issue 5, p6156-6162, 7p